- Home
- GILD vs AZN Comparison
GILD vs AZN Comparison
Compare GILD & AZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GILD | AZN |
|---|---|---|
| Founded | 1987 | 1992 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 211.7B | 250.7B |
| IPO Year | 2003 | 1995 |
Fundamental Metrics
Financial Performance| Metric | GILD | AZN |
|---|---|---|
| Price | $169.48 | $184.55 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 28 | 12 |
| Target Price | $172.50 | ★ $206.66 |
| AVG Volume (30 Days) | ★ 5.8M | 2.8M |
| Earning Date | 10-29-2026 | 10-30-2026 |
| Dividend Yield | ★ 1.93% | 1.73% |
| EPS Growth | ★ 1684.21 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $24,689,000,000.00 | N/A |
| Revenue This Year | $6.05 | $7.85 |
| Revenue Next Year | $7.18 | $6.36 |
| P/E Ratio | ★ N/A | $31.91 |
| Revenue Growth | ★ 9.98 | N/A |
| 52 Week Low | $116.88 | $81.02 |
| 52 Week High | $175.65 | $212.71 |
Technical Indicators
Market Signals| Indicator | GILD | AZN |
|---|---|---|
| Relative Strength Index (RSI) | 72.69 | 75.59 |
| Support Level | $142.91 | $180.98 |
| Resistance Level | N/A | $191.50 |
| Average True Range (ATR) | 3.98 | 2.87 |
| MACD | 1.61 | 2.31 |
| Stochastic Oscillator | 81.14 | 95.30 |
Price Performance
Historical ComparisonAbout GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
About AZN AstraZeneca PLC
A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales.